{"id":"W2963476376","doi":"10.1016/s1470-2045(19)30388-2","title":"Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study","year":2019,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1153,"is_retracted":false,"has_abstract":false,"ca_institutions":"Sunnybrook Health Science Centre; Health Sciences Centre","funders":"Merck Sharp and Dohme; Les Laboratories Pierre Fabre; Merck; Meso Scale Diagnostics; Roche; British Microcirculation Society; Amgen","keywords":"Ipilimumab; Pembrolizumab; Post-hoc analysis; Open label; Medicine; Post hoc; Oncology; Internal medicine; Clinical trial; Immunotherapy; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04835099458072202,"score_gpt":0.3901170919169451,"score_spread":0.3417660973362231,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}